Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK), the New Jersey-based maker of widely-used cancer treatment Keytruda, filed a lawsuit Tuesday in a federal court in Washington seeking to block the drug negotiation program, created by the Inflation Reduction Act of 2022, from going into effect in 2026.

Merck Sues To Stop Medicare Drug Negotiation

The drugmaker filed a lawsuit saying Medicare's drug-price negotiation program violates the company's constitutional rights.

Merck Challenges U.S. Government's New Powers to Negotiate Drug Prices

Merck & Co. MRK, +0.42% on Tuesday filed a lawsuit against the federal government over the Medicare drug price negotiation program established last year as part of the Inflation Reduction Act. The program does not involve genuine negotiation but is “tantamount to extortion,” Merck alleged in the complaint, claiming that the “singular purpose of this scheme is for Medicare to obtain prescription drugs without paying fair market value.

Merck sues federal government over Medicare drug price negotiation

The suit names as defendants the U.S. Department of Health & Human Services, its secretary Xavier Becerra, the Center for Medicare & Medicaid Services, and its administrator, Chiquita Brooks-LaSure.

Merck Sues US Over Inflation Reduction Act

In a scathing complaint filed in federal district court, Merck excoriated the Medicare price negotiation process as a "sham" and "tantamount to extortion."

Merck sues Biden administration over Medicare drug price negotiations

Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.

Merck sues US government to halt Medicare drug price negotiation

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves New Indication for Merck's PREVYMIS® for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients.

U.S. FDA Approves New Indication for Merck's PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference.

Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Merck & Co., Inc. (NYSE:MRK ) Special Event (Oncology Investor Event at ASCO 2023) June 5, 2023 7:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dean Li - President, Merck Research Laboratories Eliav Barr - SVP, Head of Global Clinical Development & Chief Medical Officer Gregory Lubiniecki - VP, Late-Stage Oncology Development Marjorie Green - SVP, Head of Late Oncology Development Chirfi Guindo - Chief Marketing Officer Scot Ebbinghaus - VP, Late Oncology Development Conference Call Participants Trung Huynh - Credit Suisse Daina Graybosch - SVB Securities Chris Schott - JPMorgan Steve Scala - Cowen & Company Seamus Fernandez - Guggenheim Securities Jon Miller - Evercore ISI Mohit Bansal - Wells Fargo Terence Flynn - Morgan Stanley Carter Gould - Barclays Louise Chen - Cantor Fitzgerald Colin Bristow - UBS Operator Welcome to the Merck & Company Incorporated Investor Events at the American Society of Clinical Oncology Annual Meeting. At this time, all participant lines are in a listen-only mode until the question and answer session of today's conference.

Merck & Co., Inc. (MRK) Presents at Special Event (Oncology Investor Event at ASCO 2023) Transcript

Merck & Co is a strong investment option due to its steady growth in the pharmaceutical industry and potential for minimal risk. The company's key products, Januvia for diabetes and Keytruda for cancer, show promising sales and growth potential. Despite some risks such as regulation and debt, Merck's financials remain strong, making it an attractive option for retail value investors.

Merck Is Climbing Higher, With Growth Potential

Moderna

Moderna MRNA, +1.55% and Merck & Co. MRK, +1.43% on Monday released new results from a trial evaluating Moderna's mRNA-based investigational individualized neoantigen therapy in combination with Merck's Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release.

Moderna and Merck reveal new data on individualized cancer treatment

Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society.

Moderna cancer vaccine used with Merck Keytruda reduces risk of deadly skin cancer spreading

Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday.

Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / June 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV). In the overall intention-to-treat (ITT) population, adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in DMFS, a key secondary endpoint of the study, compared with KEYTRUDA alone and reduced the risk of developing distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063).

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma

CMS Energy

Cisco Systems

Genuine Parts

Coca-Cola

Mondelez

Exxon Mobil

Do you ever wonder how large companies keep posting solid numbers despite the fact the economy is slowing and the consumer price index has hung right near the 5% year-over-year level?

Big Companies Keep Raising Prices: 7 ‘Strong Buy' Dividend Stocks Offer Inflation Protection

RAHWAY, N.J.--(BUSINESS WIRE)--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC.

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

Caterpillar

Wall Street has fallen back in love with rapidly growing tech companies with huge cash hoards and/or tremendous leverage to the artificial intelligence (AI) trend. Meanwhile, it's turning a cold shoulder to the blue-chip Dow Jones Industrial Average.

3 Undervalued Dow Stocks to Buy Before Wall Street Does

There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than MRK stock in the next three years.

Is Merck Stock A Better Pick Over ABBV?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC.

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Illinois Tool Works

JPMorgan Chase & Co

Lockheed Martin

Lowe's

Texas Instruments

When it comes to finding the best long-term dividend stocks to buy, yield should one be a key part of your overall criteria. It may sound tempting to build a dividend portfolio made up entirely of high-yielding names, but there are some flaws to such a strategy.

7 Dividend Stocks to Buy (and Never Sell)

Apple

NVIDIA

In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie.

3 Innovative Growth Stocks to Buy for Next-Gen Profits

Merck has been the best performing Big Pharma stock apart from Eli Lilly over the past 3 years, 1 year, and 3 months. The company drove $59.3bn of revenues in 2022, up >20%. Guidance for FY22 is for $57.7bn - $58.9bn, reflecting falling COVID antiviral sales. Keytruda is Merck's most important asset, the cancer drug driving >40% of revenues in Q1'23. Its patent protection may expire in 2028 although Merck believes they can be extended.

Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended

AstraZeneca

Merck and AstraZeneca both appear to be well-positioned for the future. Both boast above-average dividends that look to remain viable.

Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. New data for the medicines BAVENCIO® (avelumab), ERBITUX® (cetuximab), and TEPMETKO® (tepotinib) and pipeline assets including the first-in-class investigational IAP (inhibitor of apoptosis protein) inhibitor xevinap.

News for Merck Stock (MRK)